Astera Labs (NASDAQ:ALAB) Stock Price Down 8.5% - What's Next?

Key Points

• Q1 beat: Astera Labs reported EPS of $0.61 (vs. $0.54 est.) and revenue of $308.36M (+93.5% y/y), and raised Q2 guidance to $0.68–$0.70, driven by strong AI/datacenter connectivity demand.
• Despite multiple analyst upgrades and higher price targets (average target ≈ $229.65; JPMorgan $280, RBC $270), the stock traded down 8.5% intraday to about $195.65 on elevated volume, indicating profit-taking after the rally.
• Investors note a premium valuation (market cap ≈ $33.5B, P/E ~132) and material insider selling, which—along with competition and rising costs—heightens the risk that much of the upside is already priced in.

Astera Labs, Inc. (NASDAQ:ALAB - Get Free Report) traded down 8.5% during trading on Thursday . The company traded as low as $192.33 and last traded at $195.65. 6,505,664 shares changed hands during trading, an increase of 21% from the average session volume of 5,395,744 shares. The stock had previously closed at $213.91.

Astera Labs News Roundup

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Q1 results: ALAB reported a solid quarter (EPS and revenue beat, ~93% y/y revenue growth) and raised Q2 guidance, signaling strong AI/datacenter connectivity demand. This is the primary fundamental reason the stock ran higher earlier this week. Astera Labs Q1 Earnings Beat
• Positive Sentiment: Analyst upgrades/price-target increases: Multiple firms raised targets and ratings (JPMorgan raised to $280/overweight; Needham, Stifel bumped targets to $260; Susquehanna raised target to $230), reinforcing the bullish thesis that ALAB will grow with PCIe‑6 and hyperscaler AI builds. Benzinga – JPMorgan target raise JPMorgan Positive Forecast Needham Target Raised Stifel Positive Forecast
• Neutral Sentiment: Industry positioning/coverage: Analyst notes and feature pieces highlight ALAB’s leadership in internal server connectivity (X-series, Scorpio roadmap) and momentum in AI/PCIe‑6 — supportive background but not new guidance. MarketBeat – Nuts and Bolts AI Play
• Neutral Sentiment: Earnings call and analysis: Transcripts and summaries (Seeking Alpha, TipRanks) underline management’s roadmap (X-series, optical focus) and margin details; useful for longer-term investors but do not change the immediate market reaction. Earnings Call Transcript TipRanks Earnings Highlights
• Negative Sentiment: Valuation and cautionary notes: Several analysts and pieces flag a premium valuation, rising costs/competition and the risk that much of the good news is already priced in — factors that likely prompted profit-taking and the intraday pullback. Zacks – Buy/Hold/Sell Post Q1 Yahoo – Assessing Overvaluation

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Royal Bank Of Canada increased their price target on shares of Astera Labs from $250.00 to $270.00 and gave the company an "outperform" rating in a research report on Wednesday. Weiss Ratings upgraded shares of Astera Labs from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday. Loop Capital started coverage on shares of Astera Labs in a report on Thursday, March 5th. They issued a "buy" rating and a $250.00 target price on the stock. UBS Group started coverage on shares of Astera Labs in a report on Tuesday, April 21st. They issued a "neutral" rating and a $180.00 target price on the stock. Finally, Susquehanna raised their target price on shares of Astera Labs from $155.00 to $230.00 and gave the stock a "neutral" rating in a report on Wednesday. Fifteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Astera Labs presently has an average rating of "Moderate Buy" and an average price target of $229.65.

Astera Labs Stock Performance

The business has a 50-day simple moving average of $142.43 and a two-hundred day simple moving average of $153.74. The company has a market capitalization of $33.51 billion, a price-to-earnings ratio of 132.20, a PEG ratio of 4.24 and a beta of 3.35.

Astera Labs (NASDAQ:ALAB - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.54 by $0.07. The business had revenue of $308.36 million during the quarter, compared to the consensus estimate of $292.19 million. Astera Labs had a return on equity of 19.36% and a net margin of 26.72%.The company's revenue for the quarter was up 93.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.33 EPS. Astera Labs has set its Q2 2026 guidance at 0.680-0.700 EPS. Research analysts predict that Astera Labs, Inc. will post 1.48 EPS for the current fiscal year.

Insider Buying and Selling at Astera Labs

In other news, COO Sanjay Gajendra sold 94,971 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $123.81, for a total transaction of $11,758,359.51. Following the completion of the transaction, the chief operating officer directly owned 1,531,301 shares of the company's stock, valued at approximately $189,590,376.81. This represents a 5.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Michael Truett Tate sold 12,001 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $123.81, for a total value of $1,485,843.81. Following the transaction, the chief financial officer directly owned 192,083 shares of the company's stock, valued at approximately $23,781,796.23. This trade represents a 5.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 1,064,888 shares of company stock worth $150,764,723. 12.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Astera Labs

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Astera Labs by 14.1% during the third quarter. Vanguard Group Inc. now owns 13,743,141 shares of the company's stock worth $2,690,907,000 after buying an additional 1,693,918 shares in the last quarter. Atreides Management LP increased its position in Astera Labs by 2,496.6% during the fourth quarter. Atreides Management LP now owns 1,611,194 shares of the company's stock worth $268,038,000 after buying an additional 1,549,144 shares in the last quarter. Amundi increased its position in Astera Labs by 1,298.6% during the third quarter. Amundi now owns 1,421,263 shares of the company's stock worth $278,283,000 after buying an additional 1,319,643 shares in the last quarter. Rafferty Asset Management LLC purchased a new position in Astera Labs during the third quarter worth $209,599,000. Finally, BNP Paribas Financial Markets increased its position in Astera Labs by 577.3% during the third quarter. BNP Paribas Financial Markets now owns 1,127,340 shares of the company's stock worth $220,733,000 after buying an additional 960,899 shares in the last quarter. 60.47% of the stock is owned by hedge funds and other institutional investors.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company's product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.